Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Thoracic Malignancies
•
Medical Oncology
•
BRAF+
How would you treat a patient with BRAF V600E-mutated metastatic lung adenocarcinoma who has progressed on chemotherapy, immunotherapy and Dabrafenib/Trametinib?
Related Questions
Would you consider switching capmatinib to tepotinib or vice versa due to grade 3 hepatotoxicity in a patient with metastatic NSCLC with MET Exon 14 skipping mutation?
What systemic therapy would you offer to a patient with metastatic EGFR exon 19 deleted NSCLC to the brain with isolated CNS progression while on osimertinib 80 mg and progressed through WBRT?
What adjuvant therapy, if any, would you offer for a young fit patient with stage IB lung adenocarcinoma harboring an EGFR A763_Y764insFQEA who received no prior therapy?
Would you offer adjuvant pembrolizumab to a stage II-III adenocarcinoma of the lung who had a complete pathologic response to 4 cycles of cisplatin/pemetrexed/pembro (KN-671)?
In patients with driver mutation positive NSCLC who have progressed on targeted therapy and are planned for chemotherapy as the next line of treatment, for which driver alterations do you add in IO and which do you omit IO?
What is the role for molecular agents alone for medically inoperable NSCLC who is not a good candidate for chemoRT?
Which targeted therapies should we be more cautious of giving after recent immunotherapy in NSCLC?
What would be your approach in a patient who presented with a solitary brain metastasis that resolved after chemo without local therapy?
Would you offer a different ALK inhibitor to a patient receiving alectinib who had decompensation of liver function in the setting of preexisting cirrhosis?
How are you approaching patients who receive neoadjuvant chemo immunotherapy for resectable NSCLC who after completion of neoadjuvant treatment are no longer surgical candidates due to factors such as toxicity, decline in PS, or patient preference?